Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifitegrast/Perfluorohexyloctane FDC Long-Term Safety in Dry Eye Disease
NCT07111013Phase 3Withdrawn
- Sponsor
- Bausch + Lomb
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of lifitegrast, perfluorohexyloctane in dry eye disease (DED), sponsored by Bausch + Lomb. Planned start Dec 2025; status: withdrawn.
02
Drugs
lifitegrastperfluorohexyloctane
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07111013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07111013.